Gemcitabine trials for Metastatic Pancreatic Ductal Adenocarcinoma

All Gemcitabine trials · All Metastatic Pancreatic Ductal Adenocarcinoma trials

Phase breakdown

Recruiting trials studying Gemcitabine for Metastatic Pancreatic Ductal Adenocarcinoma

• BBO-11818 in Adult Subjects With KRAS Mutant Cancer
  NCT06917079 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
  NCT06904378 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
  NCT06445062 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations

Common questions

How many trials study Gemcitabine for Metastatic Pancreatic Ductal Adenocarcinoma?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.